{{Rsnum
|rsid=10937275
|Gene=ST6GAL1
|Chromosome=3
|position=186933001
|Orientation=plus
|GMAF=0.08356
|Gene_s=LDLRAD2,ST6GAL1
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|effect1=
|effect2=
|effect3=
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 0.9 | 14.2 | 85.0
| HCB | 0.0 | 0.0 | 100.0
| JPT | 0.0 | 0.0 | 100.0
| YRI | 3.4 | 17.7 | 78.9
| ASW | 0.0 | 19.3 | 80.7
| CHB | 0.0 | 0.0 | 100.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 3.0 | 97.0
| LWK | 3.6 | 22.7 | 73.6
| MEX | 1.7 | 15.5 | 82.8
| MKK | 0.6 | 23.7 | 75.6
| TSI | 1.0 | 11.8 | 87.3
| HapMapRevision=28
}}In HLA-B*5701 carrier cases, i.e. [[rs2395029]](G) carriers, [[rs10937275]] showed an increased in risk for drug-induced liver injury for patients taking [[flucloxacillin]]. The odds ratio was 4.1 (p = 1.4 x 10(-8)).{{PMID|19483685}}

{{omim
|desc=MAJOR HISTOCOMPATIBILITY COMPLEX, CLASS I, B; HLA-B
|id=142830
|rsnum=10937275
}}

{{PharmGKB
|RSID=rs10937275
|Name_s=
|Gene_s=ST6GAL1
|Feature=
|Evidence=PubMed ID:19483685
|Annotation=This intronic variant of ST6GAL1 was significantly associated with flucloxacillin-induced liver injury in a GWAS screen (OR = 4.1, P = 1.4x10-8).
|Drugs=flucloxacillin
|Drug Classes=
|Diseases=Drug Toxicity; Liver Diseases
|Curation Level=Curated
|PharmGKB Accession ID=PA164889035
}}

{{omim
|desc=HLA COMPLEX P5 GENE; HCP5
|id=604676
|rsnum=10937275
}}

{{GET Evidence
|impact=pathogenic
|qualified_impact=Insufficiently evaluated pathogenic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs10937275
|overall_frequency_n=116
|overall_frequency_d=128
|overall_frequency=0.90625
|n_genomes=52
|n_genomes_annotated=0
|n_haplomes=96
|n_articles=1
|n_articles_annotated=0
|in_gwas=Y
|in_pharmgkb=Y
|autoscore=2
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}